Swixx BioPharma is designed to fully replace biopharma, OTC and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit.With almost 300 employees and sales likely to top 120 million Euros in 2019, Swixx BioPharma is already the largest agent for ethical pharmaceuticals serving research-based biopharma in CEE. The company is staffed by a unique group of access-savvy managers and medical professionals who are dedicated to bring modern medicines to the people of CEE region. We are a service-oriented, high quality and ethically-driven company. Swixx BioPharma began operations in December 2014 and is registered in Baar, Switzerland. The company has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia and Slovenia. Both Swixx BioPharma senior management and owners come from a heritage of unique success in specialty pharmaceuticals in the CEE region. Swixx BioPharma enjoys strong financial connections with banks, hedge funds and private equity – should the need or opportunity arise, we have unsurpassed ability to raise capital quickly and efficiently
Registered in Baar, Switzerland, Swixx BioPharma SA commenced operations in late 2014. The company originally served research-based biopharma in the countries of the former Yugoslavia and the Baltic states, but subsequently expanded beginning in 2017 to cover the larger countries of CEE (Bulgaria, Czech, Hungary, Poland, Romania and Slovakia). The company intends to enter Russia during the 2H of 2019. Swixx BioPharma’s management are a proven, high-calibre team. Prior to building Swixx BioPharma into a CEE juggernaut over the last four years; prior to Swixx BioPharma, the same team had founded and built-up PharmaSwiss SA, which at the time it was sold (to Bausch Health Companies in 2011) was one of the largest (205M Euros in sales) and certainly the fastest-growing specialty pharmaceutical company in CEE.
Swixx BioPharma is focused on the CEE region•Albania•Bosnia and Herzegovina•Bulgaria•Croatia•Czech Republic•Estonia•Hungary•Kosovo•Latvia•Lithuania•Montenegro•North Macedonia•Poland•Romania•Russia•Serbia•Slovakia•SloveniaThis region comprise 121 million people and a pharmaceutical market of 15.9 billion Euros. Their economies currently are amongst the least developed in Europe, but they show considerable promise and boast well-educated and cultured people. Many western healthcare companies chose not to enter these markets, but nonetheless wish to have their products present and represented by a professional, compliant and competent regional partner. Swixx BioPharma aims to fill this need and to bring modern medicines to the people of the region.
VISION & MISSION
VISIONfor Medical Community & Patients•To resolve unmet medical needs in a cost effective, ethical manner •Always to align with EBM and best practice (patient focus)•To provide expertise, knowledge and rapid executionfor Industry Partners•To bring their innovative products to CEE, leveraging a patient-centric approach•To get novel products registered, launched and reimbursed at maximum permitted price•Provide security to our partners through robust systems in compliance, quality, pricing, medical risk-management programs, and to adhere to strict territorial limitations.for Investors•To build a global specialty pharma company with over €500m in sales within 7 yearsMISSION•Swixx BioPharma is designed to fully replace multinationals‘ subsidiaries in countries that the multinational companies choose not to enter, or choose to exit. We are an unavoidable partner in CEE •Portfolio and pipeline of our clients are our first and only priority and focus•Functional expertise and focus are designed to mirror our client‘s needs •We have one raison d‘etre: service to our senior Multinational Corporate Organization partners•Our DNA is dominated by a highly specialialized medicines, as well as a compliance-driven mentality•Rare disease focus exemplified by the creation of rare disease business unit in late 2018